# US 2016/0251377 A1 · Azaindoles as respiratory syncytial virus antiviral agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0251377 A1
- Document ID: US20160251377A1
- Status: Published application
- Kind: A1
- Application number: 15/153,591
- Filed: 2016-05-12
- Published: 2016-09-01
- Earliest claimed: 2010-12-16
- Assignees: Janssen Sciences Ireland UC
- Applicants: Janssen Sciences Ireland UC
- Inventors: Ludwig Paul Cooymans; Samuël Dominique DEMIN; Lili HU; Tim Hugo Maria JONCKERS; Pierre Jean-Marie Bernard RABOISSON; Abdellah TAHRI; Sandrine Marie Helene VENDEVILLE
- Web page: https://patentgrep.com/patent/US20160251377A1

## CPC

- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 471/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Azaindoles having inhibitory activity on RSV replication and having the formula I compositions containing these compounds as active ingredient and processes for preparing these compounds and compositions.

## Claims

### Claim at position 1

1-22. (canceled)

### Claim 23

A compound selected from the group consisting of:
and an N-oxide, addition salt, quaternary amine, or a stereochemically isomeric form thereof.

### Claim 24

A pharmaceutical composition comprising a compound selected from the group consisting of:
and an N-oxide, addition salt, quaternary amine, or a stereochemically isomeric form thereof.

### Claim 25

A method of treating a respiratory syncytial viral (RSV) infection comprising administering to a subject in need thereof an anti-virally effective amount of a compound selected from the group consisting of:
and an N-oxide, addition salt, quaternary amine, or a stereochemically isomeric form thereof.

### Claim 26

A process for preparing a compound of formula I, said process comprising coupling a compound of formula II with a compound of formula III
wherein
W is selected from the group consisting of: hydroxyl, halogen, and sulfonate;
each X independently is C or N with at least one X being N;
R1 is absent where X is N, and R1 is present where X is C, R1 being selected from the group of: H, OH, halogen, C1-C6alkyl, C3-C7cycloalkyl, C1-C6alkoxy, N(R6)2, CO(R7), CH2NH2, CH2OH, CN, C(═NOH)NH2, C(═NOCH3)NH2, C(═NH)NH2, CF3, OCF3, B(OH)2 and B(O—C1-C6alkyl)2;
R2 is selected from the group consisting of: H, halogen, C1-C6alkyl, C3-C7cycloalkyl, C1-C6alkoxy, and CO(R7);
R3 is —(CR8R9)nR10;
R4 is selected from the group consisting of: H, CH2CF3, C3-C7cycloalkyl, C2-C10alkenyl, SO2—R8, and a 4 to 6 membered saturated ring containing an oxygen atom;
R5 is present where Y is C, R5 is selected from the group consisting of H, C1-C6alkyl, C3-C7cycloalkyl, C1-C6alkoxy, CO(R7), CF3 and halogen;
R5 is absent where X is N;
R6 is selected from the group consisting of: H, C1-C6alkyl, COOCH3, and CONHSO2CH3;
R7 is selected from the group consisting of: OH, O(C1-C6alkyl), NH2, NHSO2N(C1-C6alkyl)2, NHSO2NHCH3, NHSO2(C1-C6alkyl), NHSO2(C3-C7cycloalkyl), and N(C1-C6-alkyl)2;
n is an integer from 2 to 6;
R8 and R9 are each independently selected from the group consisting of: H, C1-C10alkyl, C3-C7cycloalkyl, or R8 and R9 taken together form a 4 to 6 membered aliphatic ring that optionally contains a heteroatom selected from the group consisting of N, S and O; and
R10 is selected from the group consisting of: H, C1-C6alkyl, OH, CN, F, CF2H, CF3, CONR8R9, COOR8, CONR8SO2R9, CON(R8)SO2N(R8R9), NR8R9, NR8COOR9, OCOR8, NR8SO2R9, SO2NR8R9, SO2R8 and a 4 to 6 membered saturated ring containing an oxygen atom; and an N-oxide, addition salt, quaternary amine, or a stereochemically isomeric form thereof.

### Claim 27 (depends on 26)

The process of claim 26, wherein W is selected from the group consisting of: OH, Cl, Br, and SO3—C1-C6alkyl.

### Claim 28 (depends on 26)

The process of claim 26, wherein W is OH, and the compound of formula II and the compound of formula III are coupled in the presence of triphenyl phosphine and azadiisopropyldicarboxylate in a solvent.

### Claim 29 (depends on 26)

The process of claim 26, wherein W is halogen or sulfonate, and the compound of formula II and the compound of formula III are coupled in the presence of a base in a solvent.

### Claim 30 (depends on 29)

The process of claim 29, wherein the base is sodium hydride, potassium carbonate or cesium carbonate.

### Claim 31 (depends on 26)

The process of claim 26, wherein one X is N, and the one X that is N is in meta or para position to N—R3

### Claim 32 (depends on 26)

The process of claim 26, wherein R1 is independently selected from the group consisting of: H, OH, halogen, CF3, and C1-C6alkoxy.

### Claim 33 (depends on 26)

The process of claim 26, wherein R2 is H, halo, or C1-C6alkyl.

### Claim 34 (depends on 26)

The process of claim 26, wherein R4 is CH2CF3, C3-C7cycloalkyl or a 4 membered saturated hydrocarbon containing an oxygen atom.

### Claim 35 (depends on 26)

The process of claim 26, wherein R5 is H or halogen.

### Claim 36 (depends on 26)

The process of claim 26, wherein R8 and R9 are H, and n is 2-4.

### Claim 37 (depends on 26)

The process of claim 26, wherein R10 is OH, CN, F, CO2C(CH3)3, SO2CH3, or C1-C6alkyl.

### Claim 38 (depends on 29)

The process of claim 29, wherein
one X is N, and the one X that is N is in meta or para position to N—R3, and when X is N, said R1 is absent;
R1 is independently selected from the group consisting of: H, OH, halogen, CF3, and C1-C6alkoxy;
R2 is H, halo, or C1-C6alkyl
R3 is —(CR8R9)n—R10; R8 and R9 are independently H and C1-C10alkyl; n is 2-4; and
R10 is OH, CN, F, CO2C(CH3)3, SO2CH3, or C1-C6alkyl.

### Claim 39

A compound selected from the group consisting of:
Ethyl 1-(4-(tert-butyldimethylsilyloxy)butyl)-1H-pyrrolo[3,2-c]pyridine-2-carboxylate;
(1-(4-(tert-Butyldimethylsilyloxy)butyl)-1H-pyrrolo[3,2-c]pyridin-2-yl)methanol;
3-((1-(4-(tert-Butyldimethylsilyloxy)butyl)-1H-pyrrolo[3,2-c]pyridin-2-yl)methyl)-1-cyclopropyl-1H-imidazo[4,5-c]pyridin-2(3H)-one;
Ethyl 5-chloro-1-(4-fluorobutyl)-1H-pyrrolo[2,3-c]pyridine-2-carboxylate;
(5-Chloro-1-(4-fluorobutyl)-1H-pyrrolo[2,3-c]pyridin-2-yl)methanol;
Methyl 5-chloro-1-(4-fluorobutyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylate;
(5-Chloro-1-(4-fluorobutyl)-1H-pyrrolo[3,2-b]pyridin-2-yl)methanol;
Methyl 5-chloro-1-(4,4,4-trifluorobutyl)-1H-pyrrolo[3,2-b]pyridine-2-carboxylate;
(5-Chloro-1-(4,4,4-trifluorobutyl)-1H-pyrrolo[3,2-b]pyridin-2-yl)methanol;
Methyl 3-bromo-1-(3-(methylsulfonyl)propyl)-1H-pyrrolo[3,2-c]pyridine-2-carboxylate; and
(3-Bromo-1-(3-(methylsulfonyl)propyl)-1H-pyrrolo[3,2-c]pyridin-2-yl)methanol;
and an N-oxide, addition salt, quaternary amine, or a stereochemically isomeric form thereof.
